Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
Human immunodeficiency virus (HIV)-infected, active intravenous drug users received once-daily therapy consisting of a combination of didanosine (2',3'-dideoxyinosine or DDI), lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine or 3TC] and nevirapine. Preliminary results for the first 24 weeks show that the regimen provides potent immunological and antiviral effects.
Staszewski
S
S
Klinikum der JW Goethe-Universität Frankfurt, Zentrum der Inneren Medizin, Germany. staszewski@em.uni-frankfurt.de
Haberl
A
A
Gute
P
P
Nisius
G
G
Miller
V
V
Carlebach
A
A
D000328:Adult; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D019829:Nevirapine / Q000008:administration & dosage*; D010865:Pilot Projects; D011446:Prospective Studies; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000188:drug therapy; D019562:Viral Load
D019259:Lamivudine; D019829:Nevirapine; D016049:Didanosine; D008691:Methadone